Wiener Privatklinik
Wiener Privatklinik
Austria, Vienna
Christoph Zielinski
44 years of experience
accreditations :
Clinic is certified :
Small intestine cancer treatment cost in Austria typically includes essential diagnostics like a consultation with an oncologist, which ranges from $200 to $400. Primary surgical procedures such as a small intestine resection run from $25,000 to $38,000. Final expenses depend on the cancer stage, clinic tier, and specific treatment protocols. Patients can expect 20-30% savings compared to the US, primarily in Vienna, Salzburg, or Innsbruck.
Typical Small Intestine Cancer Treatment Costs in Austria
Bookimed Expert Insight: Advanced stage patients requiring multidisciplinary care should consider Wiener Privatklinik. Their International Oncology Center features experts like Univ.-Prof. Dr. Wolfgang Köstler, specializing in immunotherapy and personalized medicine. For those prioritizing safety, Döbling Private Hospital maintains complication rates significantly below average. These private Vienna clinics offer high-tier medical expertise typically 20-30% more affordably than equivalent US private centers.
| Turkey | Austria | Spain | |
| Small intestine resection | from $12,150 | from $25,000 | from $18,000 |
| Radiation therapy for colorectal cancer | from $7,000 | from $12,000 | from $10,000 |
| Radiation therapy for bowel cancer | from $5,800 | from $6,913 | from $4,033 |
| Hyperthermic Intraperitoneal Chemotherapy (HIPEC) | from $22,500 | from $40,000 | from $25,000 |
| Chemotherapy for breast cancer | from $1,200 | from $15,000 | from $3,500 |
As an Associate Professor and former Deputy Head of Oncology at the Medical University of Vienna, Prof. Köstler focuses on targeted, personalized cancer medicine.
The doctor is a leading figure in medical oncology, hematology, and cancer immunotherapy, with a career spanning over four decades. After earning a medical degree from the University of Vienna in the 1970s, the doctor completed specialist training in internal medicine and oncology in the 1980s.
In the 1990s, the doctor was appointed Head of the Clinical Division of Oncology at the Medical University of Vienna, leading Austria's largest oncology department. The 2000s saw the founding of the Comprehensive Cancer Center Vienna, integrating patient care, research, and education.
The doctor served as President of the Central European Cooperative Oncology Group in the 2010s and currently holds positions as Chairman of the Vienna Cancer Center and Medical Director of Wiener Privatklinik’s International Oncology Center.
The doctor completed medical studies at the University of Vienna in 1998, with training at UCLA and the University of Pennsylvania. From 2000 to 2006, the doctor trained as a specialist in internal medicine at Vienna General Hospital, followed by additional specialization in gastroenterology and hepatology from 2006 to 2008, and internal intensive care medicine from 2008 to 2010.
The doctor established and managed the hepatic hemodynamics laboratory and the outpatient clinic for cirrhosis at the Medical University of Vienna in 2003. Since 2018, the doctor has been head of the Department for Internal Medicine I at the Hospital of the Barmherzigen Brüder Vienna.
Treatment for small intestine cancer in Austria centers on surgical resection combined with systemic therapies like chemotherapy and immunotherapy. Leading Viennese private hospitals utilize multidisciplinary oncology boards. Treatments follow European Society for Medical Oncology guidelines. Personalized protocols often include targeted drugs for specific genetic mutations or histotypes.
Bookimed Expert Insight: Advanced oncology care in Vienna is highly concentrated. Wiener Privatklinik and Döbling Private Hospital provide access to professors from the Medical University of Vienna. These specialists often lead early clinical trials for targeted therapies. This means patients receive treatment from the same experts who develop international protocols. Döbling Private Hospital also maintains complication rates significantly below international nominal values.
Patient Consensus: Many emphasize getting a second opinion from a multidisciplinary tumor board for this rare diagnosis. After surgery, patients often note that dietary support is vital for managing recovery-related weight loss.
Austria ranks among the top 10 global healthcare systems, offering elite standards for small intestine cancer care. Medical centers in Vienna provide advanced multidisciplinary treatments. These include precision medicine, immunotherapy, and complex procedures like Hyperthermic Intraperitoneal Chemotherapy. Facilities maintain rigorous International Organization for Standardization (ISO) certifications.
Bookimed Expert Insight: While many countries offer general oncology, Austria focuses on centralized expertise within private-public partnerships. For example, Amethyst Radiotherapy Austria operates directly within Wiener Privatklinik. This creates a one-stop hub where specialized radiation and surgical oncology teams collaborate daily. This integration can significantly reduce the time between diagnosis and the start of treatment.
Patient Consensus: Patients note that receiving care at centers that utilize multidisciplinary tumor boards is essential for rare gastrointestinal cancers. They emphasize the importance of confirming that surgeons have specific experience with duodenal or small bowel tumors before proceeding.
Austria treats small intestine cancer at specialized university hospitals and private clinics in Vienna and Innsbruck. These centers utilize multidisciplinary tumor boards and advanced visceral surgery. Facilities like Wiener Privatklinik and AKH Vienna offer specialized resection and targeted oncology protocols.
Bookimed Expert Insight: Choosing a hospital in Vienna like Wiener Privatklinik provides unique access to academic expertise. Over 400 physicians work there. Many are also professors at the Medical University of Vienna. This structure allows patients to receive private care from researchers who develop the latest protocols. This specific link between private facilities and university research is a hallmark of Austrian oncology care.
Patient Consensus: Patients emphasize finding a major university hospital with a multidisciplinary team for rare tumors. They note that having pathologies re-reviewed by experienced academic centers ensures the most accurate treatment plan.
Qualified Austrian oncologists for small intestine cancer must be board-certified in internal medicine and medical oncology. Prioritize specialists at university-affiliated clinics who lead multidisciplinary tumor boards. These experts should demonstrate expertise in targeted therapies and molecular genetic testing for rare gastrointestinal malignancies.
Bookimed Expert Insight: Austrian oncology is unique because top university professors often consult at private facilities like Wiener Privatklinik. This allows patients to access academic-level expertise in a private hospital setting with 130 beds. You get university-grade treatment protocols without the typical wait times of public research institutions.
Patient Consensus: Patients emphasize finding a doctor who distinguishes between small-bowel adenocarcinoma and neuroendocrine tumors. They note it is important to choose specialists who coordinate closely with surgeons and radiologists.
International patients are legally eligible for small intestine cancer clinical trials in Austria. EU Regulation 536/2014 permits enrollment regardless of nationality. Acceptance depends on meeting specific medical criteria. Patients must also manage complex administrative, linguistic, and financial requirements for cross-border participation.
Bookimed Expert Insight: Clinical trials for rare gastrointestinal cancers often require specific molecular markers. Univ. Prof. Dr. Wolfgang Köstler at Wiener Privatklinik specializes in individualized cancer treatments and targeted therapies. His research focus on resistance mechanisms suggests that patients with rare small intestine tumors should prioritize centers with strong biomarker-driven protocols over those using generic site-specific approaches. This targeted focus may improve eligibility for basket trials that accept various solid tumors based on genetic mutations rather than just primary organ site.
Patient Consensus: Patients find that having original pathology slides and molecular reports ready for re-review prevents major delays. They emphasize that while the experimental drug is free, the logistics and frequent travel visits are the hardest part to manage.